In this context, it was shown that deletion of corticotropin-releasing factor receptor type 1 (CRFR1) mitigated the amyloid-β pathology in a mouse model of AD, lending support to the notion that suppressing the HPA axis through CRFR1 antagonism may be an effective therapeutic strategy against AD [43]. The gene discussed is CRHR1; the disease is Alzheimer disease.